Mydecine Innovations Group Receives Conditional Approval to

Mydecine Innovations Group Receives Conditional Approval to List on NEO Exchange
Mydecine Innovations Group an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange . Final approval is subject to the Company fulfilling all of NEO’s listing requirements. With the impending …
Mydecine Innovations Group (CSE: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for mainstream use, announced today that it has received Conditional Approval to migrate and uplist its common shares with the NEO Exchange (“NEO”). Final approval is subject to the Company fulfilling all of NEO’s listing requirements.

Related Keywords

Canada , Denver , Colorado , United States , Canadian , Josh Bartch , Charles Lee , Joshua Bartch , Anne Donohoe Nick Opich , Mydecine Innovations Group Inc , Corp Communication , Strategic Communications , Mydecine Innovations Group , Twitter , Health Canada , Mydecine Innovations Group Media Contacts , Conditional Approval , Innovations Group , Innovations Group Media Contacts , Nick Opich , Chief Executive Officer , Investor Relations , கனடா , டென்வர் , கொலராடோ , ஒன்றுபட்டது மாநிலங்களில் , கனடியன் , சார்லஸ் லீ , கார்ப் தொடர்பு , மூலோபாய தகவல்தொடர்புகள் , ட்விட்டர் , ஆரோக்கியம் கனடா , நிபந்தனை ஒப்புதல் , புதுமைகள் குழு , புதுமைகள் குழு மீடியா தொடர்புகள் , தலைமை நிர்வாகி அதிகாரி , முதலீட்டாளர் உறவுகள் ,